Cargando…

Amino acid management of Parkinson’s disease: a case study

An extensive list of side effects and problems are associated with the administration of l-dopa (l-3, 4-dihydroxyphenylalanine) during treatment of Parkinson’s disease. These problems can preclude achieving an optimal response with l-dopa treatment. PURPOSE: To present a case study outlining a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinz, Marty, Stein, Alvin, Uncini, Thomas
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068871/
https://www.ncbi.nlm.nih.gov/pubmed/21475622
http://dx.doi.org/10.2147/IJGM.S16621
_version_ 1782201279488983040
author Hinz, Marty
Stein, Alvin
Uncini, Thomas
author_facet Hinz, Marty
Stein, Alvin
Uncini, Thomas
author_sort Hinz, Marty
collection PubMed
description An extensive list of side effects and problems are associated with the administration of l-dopa (l-3, 4-dihydroxyphenylalanine) during treatment of Parkinson’s disease. These problems can preclude achieving an optimal response with l-dopa treatment. PURPOSE: To present a case study outlining a novel approach for the treatment of Parkinson’s disease that allows for management of problems associated with l-dopa administration and discusses the scientific basis for this treatment. PATIENTS AND METHODS: The case study was selected from a database containing 254 Parkinson’s patients treated in developing and refining this novel approach to its current state. The spectrum of patients comprising this database range from newly diagnosed, with no previous treatment, to those who were diagnosed more than 20 years before and had virtually exhausted all medical treatment options. Parkinson’s disease is associated with depletion of tyrosine hydroxylase, dopamine, serotonin, and norepinephrine. Exacerbating this is the fact that administration of l-dopa may deplete l-tyrosine, l-tryptophan, 5-hydroxytryptophan (5-HTP), serotonin, and sulfur amino acids. The properly balanced administration of l-dopa in conjunction with 5-HTP, l-tyrosine, l-cysteine, and cofactors under the guidance of organic cation transporter functional status determination (herein referred to as “OCT assay interpretation”) of urinary serotonin and dopamine, is at the heart of this novel treatment protocol. RESULTS: When 5-HTP and l-dopa are administered in proper balance along with l-tyrosine, l-cysteine, and cofactors under the guidance of OCT assay interpretation, the long list of problems that can interfere with optimum administration of l-dopa becomes controllable and manageable or does not occur at all. Patient treatment then becomes more effective by allowing the implementation of the optimal dosing levels of l-dopa needed for the relief of symptoms without the dosing value barriers imposed by side effects and adverse reactions seen in the past.
format Text
id pubmed-3068871
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30688712011-04-07 Amino acid management of Parkinson’s disease: a case study Hinz, Marty Stein, Alvin Uncini, Thomas Int J Gen Med Case Report An extensive list of side effects and problems are associated with the administration of l-dopa (l-3, 4-dihydroxyphenylalanine) during treatment of Parkinson’s disease. These problems can preclude achieving an optimal response with l-dopa treatment. PURPOSE: To present a case study outlining a novel approach for the treatment of Parkinson’s disease that allows for management of problems associated with l-dopa administration and discusses the scientific basis for this treatment. PATIENTS AND METHODS: The case study was selected from a database containing 254 Parkinson’s patients treated in developing and refining this novel approach to its current state. The spectrum of patients comprising this database range from newly diagnosed, with no previous treatment, to those who were diagnosed more than 20 years before and had virtually exhausted all medical treatment options. Parkinson’s disease is associated with depletion of tyrosine hydroxylase, dopamine, serotonin, and norepinephrine. Exacerbating this is the fact that administration of l-dopa may deplete l-tyrosine, l-tryptophan, 5-hydroxytryptophan (5-HTP), serotonin, and sulfur amino acids. The properly balanced administration of l-dopa in conjunction with 5-HTP, l-tyrosine, l-cysteine, and cofactors under the guidance of organic cation transporter functional status determination (herein referred to as “OCT assay interpretation”) of urinary serotonin and dopamine, is at the heart of this novel treatment protocol. RESULTS: When 5-HTP and l-dopa are administered in proper balance along with l-tyrosine, l-cysteine, and cofactors under the guidance of OCT assay interpretation, the long list of problems that can interfere with optimum administration of l-dopa becomes controllable and manageable or does not occur at all. Patient treatment then becomes more effective by allowing the implementation of the optimal dosing levels of l-dopa needed for the relief of symptoms without the dosing value barriers imposed by side effects and adverse reactions seen in the past. Dove Medical Press 2011-02-28 /pmc/articles/PMC3068871/ /pubmed/21475622 http://dx.doi.org/10.2147/IJGM.S16621 Text en © 2011 Hinz et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Report
Hinz, Marty
Stein, Alvin
Uncini, Thomas
Amino acid management of Parkinson’s disease: a case study
title Amino acid management of Parkinson’s disease: a case study
title_full Amino acid management of Parkinson’s disease: a case study
title_fullStr Amino acid management of Parkinson’s disease: a case study
title_full_unstemmed Amino acid management of Parkinson’s disease: a case study
title_short Amino acid management of Parkinson’s disease: a case study
title_sort amino acid management of parkinson’s disease: a case study
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068871/
https://www.ncbi.nlm.nih.gov/pubmed/21475622
http://dx.doi.org/10.2147/IJGM.S16621
work_keys_str_mv AT hinzmarty aminoacidmanagementofparkinsonsdiseaseacasestudy
AT steinalvin aminoacidmanagementofparkinsonsdiseaseacasestudy
AT uncinithomas aminoacidmanagementofparkinsonsdiseaseacasestudy